BadeschDB, ChampionHC, SanchezMA, et al.: Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2009; 54:S55–S66.
2.
D'AlonzoGE, BarstRJ, AyresSM, et al.: Survival in patients with primary pulmonary hypertension: Results from a national prospective registry. Ann Intern Med, 1991; 115:343–349.
3.
HoeperM, KramerT, PanZ, et al.: Mortality in pulmonary arterial hypertension: Prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J, 2017; 50:pii: 1700740.
4.
GalièN, GhofraniHA, TorbickiA, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med, 2005; 353:2148–2157.
5.
GalièN, BrundageBH, GhofraniHA, et al.: Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009; 119:2894–2903.
6.
KimeuAK and SwetzKM: Moving beyond stigma—Are concurrent palliative care and management of pulmonary arterial hypertension irreconcilable or future best practice?. Int J Clin Pract Suppl, 2012:2–4.
7.
MaturaLA, McDonoughA, CarrollDL: Cluster analysis of symptoms in pulmonary arterial hypertension: A pilot study. Eur J Cardiovasc Nurs, 2012; 11:51–61.
8.
AngalakuditiM, EdgellE, BeardsworthA, et al.: Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. J Med Econ, 2010; 13:393–402.
9.
PulidoT, AdzerikhoI, ChannickRN, et al.: Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med, 2013; 369:809–818.
10.
TaichmanDB, ShinJ, HudL, et al.: Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res, 2005; 6:92.
11.
Gomberg-MaitlandM, ThenappanT, RizviK, et al.: United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant, 2008; 27:124–130.
12.
SwetzKM, ShanafeltTD, DrozdowiczLB, et al.: Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey. J Heart Lung Transplant, 2012; 31:1102–1108.
13.
McCollisterDH, BeutzM, McLaughlinV, et al.: Depressive symptoms in pulmonary arterial hypertension: Prevalence and association with functional status. Psychosomatics, 2010; 51:339–339.e8.
14.
GalièN, CorrisPA, FrostA, et al.: Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol, 2013; 62:D60–D72.
15.
HumbertM, SitbonO, SimmoneauG: Treatment of pulmonary arterial hypertension. N Engl J Med, 2004; 351:1425–1436.
16.
FenstadER, ShanafeltTD, SloanJA, et al.: Physician attitudes toward palliative care for patients with pulmonary arterial hypertension: Results of a cross-sectional survey. Pulm Circ, 2014; 4: 504–510.
17.
FenstadE, WordinghamSE, SwetzKM, et al.: Pulmonary hypertension and palliative care: What, when, where, and why?. Adv Pulm Hypertens, 2016; 15:26–31.
18.
BenzaR, Gomberg-MaitlandM, MillerDP, et al.: The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest, 2010; 121:354–362.
19.
AlamiS, CottinV, MouthonL, et al.: Patients', relatives', and practitioners' views of pulmonary arterial hypertension: A qualitative study. Presse Med, 2016; 45:e11–e27.
20.
HeoS, DoeringLV, WidenerJ, MoserDK: Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure. Am J Crit Care, 2008; 17:124–132.
21.
GrinnanDC, SwetzKM, PinsonJ, et al.: The end-of-life experience for a cohort of patients with pulmonary arterial hypertension. J Palliat Med, 2012; 15:1065–1070.
